Red blood cell distribution width as long-term prognostic markers in patients with coronary artery disease undergoing percutaneous coronary intervention
Red blood cell distribution width as long-term prognostic markers in patients with coronary artery disease undergoing percutaneous coronary intervention
复制标题
红细胞分布宽度作为冠状动脉疾病经皮冠状动脉介入治疗患者的长期预后标志物
DOI:
10.1186/s12944-019-1082-8
复制
发表时间:
2019-06-12
影响因子:
4.5
通讯作者:
Xie, Xiang
中科院分区:
文献类型:
--
作者:
Wu, Ting-Ting;Zheng, Ying-Ying;Xie, Xiang
BackgroundThe aim of this study was to assess the prognostic value of red blood cell distribution width (RDW) in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).MethodsA retrospective cohort study (CORFCHD-PCI, [Identifier: ChiCTR-INR-16010153]) of 6050 patients who were hospitalized with a diagnosis of coronary artery disease (CAD) and treated with PCI from January 2008 to December 2016 were enrolled in the study. The primary outcome was long-term mortality after PCI. Clinical follow-up data of participating patients were obtained during an outpatient examination 35.9 ± 22.6 months after PCI. Demographic and clinical data and admission laboratory parameters were recorded, and patients were categorized into two groups according to RDW level (high group ≥13.1%; low group < 13.1%).ResultsMultivariate Cox regression analysis revealed RDW as an independent prognosis factor for cardiac death. The incidence of cardiac death increased 1.33 times in patients in the high RDW group (HR, 1.331; 95% CI, 1.009–1.755,P= 0.043). Kaplan–Meier survival analysis suggested that patients with high RDW tended to have an increased accumulated risk of cardiac death. However, we did not found significant differences in the incidence of long-term mortality (adjusted HR = 1.203[0.941–1.537],P= 0.140), MACCE (adjusted HR = 1.128[0.979–1.301],P= 0.096), MACE (adjusted HR = 1.155[0.994–1.341],P= 0.059), stroke, bleeding events or readmission between the two groups.ConclusionThe baseline level of RDW is an independent predictor for cardiac death in post-PCI CAD patients.